G. Izquierdo
G. Izquierdo
Hospital Vithas Sevilla
Verified email at - Homepage
Cited by
Cited by
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis
JA Cohen, F Barkhof, G Comi, HP Hartung, BO Khatri, X Montalban, ...
New England Journal of Medicine 362 (5), 402-415, 2010
Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor
V Rothhammer, ID Mascanfroni, L Bunse, MC Takenaka, JE Kenison, ...
Nature medicine 22 (6), 586-597, 2016
Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis
JWL Brown, A Coles, D Horakova, E Havrdova, G Izquierdo, A Prat, ...
Jama 321 (2), 175-187, 2019
Defining secondary progressive multiple sclerosis
J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ...
Brain 139 (9), 2395-2405, 2016
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
A He, B Merkel, JWL Brown, LZ Ryerson, I Kister, CB Malpas, S Sharmin, ...
The Lancet Neurology 19 (4), 307-316, 2020
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis
FJ Quintana, MF Farez, V Viglietta, AH Iglesias, Y Merbl, G Izquierdo, ...
Proceedings of the National Academy of Sciences 105 (48), 18889-18894, 2008
Geographical variations in sex ratio trends over time in multiple sclerosis
M Trojano, G Lucchese, G Graziano, BV Taylor, S Simpson Jr, V Lepore, ...
PloS one 7 (10), e48078, 2012
MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis
H Butzkueven, J Chapman, E Cristiano, F Grand’Maison, M Hoffmann, ...
Multiple Sclerosis Journal 12 (6), 769-774, 2006
Toll-like receptor 2 and poly (ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE
MF Farez, FJ Quintana, R Gandhi, G Izquierdo, M Lucas, HL Weiner
Nature immunology 10 (9), 958-964, 2009
Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis
VG Jokubaitis, T Spelman, T Kalincik, J Lorscheider, E Havrdova, ...
Annals of neurology 80 (1), 89-100, 2016
Defining reliable disability outcomes in multiple sclerosis
T Kalincik, G Cutter, T Spelman, V Jokubaitis, E Havrdova, D Horakova, ...
Brain 138 (11), 3287-3298, 2015
Predictors and dynamics of postpartum relapses in women with multiple sclerosis
SE Hughes, T Spelman, OM Gray, C Boz, M Trojano, A Lugaresi, ...
Multiple Sclerosis Journal 20 (6), 739-746, 2014
Sex as a determinant of relapse incidence and progressive course of multiple sclerosis
T Kalincik, V Vivek, V Jokubaitis, J Lechner-Scott, M Trojano, G Izquierdo, ...
Brain 136 (12), 3609-3617, 2013
Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS
KA Ribbons, P McElduff, C Boz, M Trojano, G Izquierdo, P Duquette, ...
PloS one 10 (6), e0122686, 2015
Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis
T Kalincik, D Horakova, T Spelman, V Jokubaitis, M Trojano, A Lugaresi, ...
Annals of Neurology 77 (3), 425-435, 2015
Multiple Sclerosis Risk Variant HLA-DRB1*1501 Associates with High Expression of DRB1 Gene in Different Human Populations
A Alcina, MM Abad-Grau, M Fedetz, G Izquierdo, M Lucas, O Fernandez, ...
PloS one 7 (1), e29819, 2012
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
T Kalincik, JWL Brown, N Robertson, M Willis, N Scolding, CM Rice, ...
The Lancet Neurology 16 (4), 271-281, 2017
Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations
G Kristjansdottir, JK Sandling, A Bonetti, IM Roos, L Milani, C Wang, ...
Journal of medical genetics 45 (6), 362-369, 2008
Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis
L Kappos, M Mehling, R Arroyo, G Izquierdo, K Selmaj, V Curovic-Perisic, ...
Neurology 84 (9), 872-879, 2015
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
D Cadavid, M Mellion, R Hupperts, KR Edwards, PA Calabresi, J Drulović, ...
The Lancet Neurology 18 (9), 845-856, 2019
The system can't perform the operation now. Try again later.
Articles 1–20